Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products
Xintela and EQGen Biomedical Inc. (“EQGen”) have signed the definitive collaboration and license agreement, contemplated by their previously announced term sheet, for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and […]
Xintela decreases patient number in XSTEM clinical study in difficult-to-heal venous leg ulcers
Xintela has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enrolled in the study has been reduced from 12 to 6. The primary goal of the study, to investigate safety and tolerability, will […]
Xintela’s stem cell product XSTEM shows safety and positive efficacy results in knee osteoarthritis clinical study
Xintela’s interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend […]
Xintela AB Year-end Report 2024
Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2024Income amounted to TSEK 1,090 (78).Loss before tax totalled TSEK 11,712 (loss: 12,175).Loss per share* was SEK 0.02 (loss: 0.03). Full year 2024Income amounted to TSEK 4,215 (78).Loss before tax totalled TSEK 41,534 (loss: 58,367).Loss […]
Xintela AB Interim Report January – September 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2024Income amounted to TSEK 2,822 (0).Loss before tax totalled TSEK 8,049 (loss: 11,953).Loss per share was SEK 0.01 (loss: 0.02). First nine month 2024Income amounted to TSEK 3,125 (0).Loss before tax totalled TSEK 29,821 (loss: 46,192).Loss […]
Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million
Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s […]
Xintela AB Interim Report January – June 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients
Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]
Xintela AB Interim Report January – March 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2024 for the groupIncome amounted to TSEK 299 (0).Loss before tax totalled TSEK 11,372 (loss: 15,843).Loss per share was SEK 0.02 (loss: 0.05). First quarter 2024 for the parent companyIncome amounted to TSEK 299 (0).Loss before […]
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]
